Who
Philip P. Boudreau
EVP and CFO
Company insider
Files Form 4 as: EVP and CFO, Abbott Laboratories.
In numbers
- Trades disclosed
- 38
- Buys
- 1
- Sells
- 4
- Bought
- $403K
- Sold
- $3.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 13 Mar 2020
- Last trade
- 1 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 3 Sep 2026 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Code F | $43K388 at $110.36 | filing |
| 1 Sep 2026filed 3 Sep 2026 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Code F | $43K388 at $110.36 | filing |
| 23 Apr 2026filed 27 Apr 2026 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Code I | $820K8,909 at $92.04 | filing |
| 23 Apr 2026filed 27 Apr 2026 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Bought | $201K2,200 at $91.50 | filing |
| 23 Apr 2026filed 27 Apr 2026 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Code I | $820K8,909 at $92.04 | filing |
| 23 Apr 2026filed 27 Apr 2026 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Bought | $201K2,200 at $91.50 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Code F | $865K7,441 at $116.26 | filing |
| 27 Feb 2026filed 3 Mar 2026 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Code F | $865K7,441 at $116.26 | filing |
| 24 Feb 2026filed 26 Feb 2026 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Code A | —27,997 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | ABT Abbott Laboratoriesoption or derivative · Biotechnology | SEC FORM 4 Code A | —115,413 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | ABT Abbott Laboratoriesoption or derivative · Biotechnology | SEC FORM 4 Code A | —115,413 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Code A | —27,997 at $0.00 | filing |
| 1 Sep 2025filed 3 Sep 2025 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Code F | $51K387 at $132.66 | filing |
| 8 Aug 2025filed 11 Aug 2025 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Sold | $747K5,550 at $134.55 | filing |
| 28 Feb 2025filed 4 Mar 2025 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Code F | $667K4,908 at $135.87 | filing |
| 25 Feb 2025filed 27 Feb 2025 | ABT Abbott Laboratoriesoption or derivative · Biotechnology | SEC FORM 4 Code A | —83,783 at $0.00 | filing |
| 25 Feb 2025filed 27 Feb 2025 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Code A | —22,495 at $0.00 | filing |
| 1 Sep 2024filed 4 Sep 2024 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Code F | $44K387 at $113.27 | filing |
| 29 Feb 2024filed 4 Mar 2024 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Code F | $209K1,738 at $120.05 | filing |
| 21 Feb 2024filed 23 Feb 2024 | ABT Abbott Laboratoriesoption or derivative · Biotechnology | SEC FORM 4 Code A | —86,519 at $0.00 | filing |
News
Abbott Laboratories (NYSE:ABT) Given "Buy" Rating at TD CowenABT · dailypolitical.com · 16 Oct 2026Abbott Laboratories is More than a Dividend Stock. Here's Why.ABT · insidermonkey.com · 11 Oct 2026Barclays Initiates Coverage on Abbott Laboratories (NYSE:ABT)ABT · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Philip P. Boudreau; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.